Nomura: Rongchang Bio's new H-share issuance improves financial condition, raising target price by 190.8%.

Jin10 reported on May 23 that Nomura's research report indicates that the placement of new H shares by Rongchang Bio (09995.HK) is favourable for the group's financial situation. The bank believes that the current strong sentiment in the market towards biotechnology companies provides a good issuance opportunity for the group. At the same time, the 800 million HKD raised from the placement will strengthen the group's limited cash position. The bank also believes that the prospects for asset licensing have become brighter, thus raising the group's target price by 190.8%, from 16.37 HKD to 47.6 HKD. The rating remains at "Neutral."

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)